亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Auristatin Tyramine Phosphate Prodrugs and Aminoquinoline Derivatives

標題
Auristatin Tyramine Phosphate Salts and Auristatin Aminoquinoline Derivatives and Prodrugs Thereof
詳細技術說明
The remarkable anticancer properties of dolastatin 10, isolated from the sea hare (sea slug) Dolabella auricularia, have led to interest in closely related derivatives (auristatins) suitable for clinical trials. Most recently, such auristatins have been linked to antibodies for delivery. In many indications, however, it would be desirable to deliver such drugs without resort to conjugation. Researchers at Arizona State University have developed prodrug forms of a novel auristatin tyramine derivative as phosphate salts, as well as auristatin quinoline modifications. These compounds exhibit superior inhibition of cancer cell growth. In addition, auristatin TP sodium salt is water soluble, and is thus expected to have greater bioavailability. Existing auristatin drugs (e.g., SGN-35) are showing promise in clinical trials. The above novel compounds may have important advantages over such existing auristatin drugs and may prove to be important drugs for treating cancer. Potential Applications Inhibiting cancer cell growth Treating many types of cancer Benefits and Advantages Novel compounds displayed very strong cancer cell growth inhibition against a panel of murine and human cancer cell lines Auristatin TP sodium salt: Water soluble No need for conjugation to a macromolecule, such as an antibody, for delivery Likely greater bioavailability than other forms of the drug Auristatins 2-AQ and 6-AQ Aminoquinoline modifications of dolastatin 10 Various biological activities have been reported for simple derivatives of aminoquinolines, and these moieties are expected to confer distinct activity Suitable for attachment to an antibody For more information about the inventor(s) and their research, please see Dr. Pettit's departmental webpage
*Abstract
None
*IP Issue Date
Jun 2, 2015
*Principal Investigation

Name: George (bob) Pettit, Regents' Professor -FY18

Department: CLAS - Molecular Sciences -FY18


Name: Fiona Hogan, Non-ASU -FY18

Department: Non-ASU -FY18


Name: Steven Toms, Non-ASU -FY18

Department: Non-ASU -FY18

申請日期
Mar 29, 2012
申請號碼
9,044,518
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備